Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.

But not every company with momentum is a long-term winner, and plenty of investors have lost money betting on short-term fads. On that note, here are three stocks that are likely overheated and some you should look into instead.

Portillo's (PTLO)

One-Month Return: +21.3%

Begun as a Chicago hot dog stand in 1963, Portillo’s (NASDAQ: PTLO) is a casual restaurant chain that serves Chicago-style hot dogs and beef sandwiches as well as fries and shakes.

Why Do We Avoid PTLO?

1. Lagging same-store sales over the past two years suggest it might have to change its pricing and marketing strategy to stimulate demand
2. Lacking free cash flow margin got worse over the last year as its investment needs accelerated
3. Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders

At $6.46 per share, Portillo's trades at 35.3x forward P/E. To fully understand why you should be careful with PTLO, check out our full research report (it’s free).

West Pharmaceutical Services (WST)

One-Month Return: +27.3%

Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE: WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products.

Why Are We Hesitant About WST?

1. Sales trends were unexciting over the last two years as its 4.9% annual growth was below the typical healthcare company
2. Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 5.8 percentage points
3. Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability

West Pharmaceutical Services is trading at $312.13 per share, or 33.2x forward P/E. Check out our free in-depth research report to learn more about why WST doesn’t pass our bar.

Oracle (ORCL)

One-Month Return: +21.1%

Starting as a database company in 1977 and now powering mission-critical systems across the globe, Oracle (NYSE: ORCL) provides enterprise software and hardware products and services that help businesses manage their information technology needs.

Why Are We Cautious About ORCL?

1. Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 10.1% for the last five years
2. Cash burn makes us question whether it can achieve sustainable long-term growth
3. Unfavorable liquidity position could lead to additional equity financing that dilutes shareholders

Oracle’s stock price of $178.18 implies a valuation ratio of 6.7x forward price-to-sales. If you’re considering ORCL for your portfolio, see our FREE research report to learn more.

High-Quality Stocks for All Market Conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.